Due to the rareness of immunohistochemically detectable INHA expression in most cancer types, we were only able to compare INHA immunostaining data with available clinical data in neuroendocrine tumors, clear cell renal cell carcinoma, and colorectal adenocarcinoma. This evidence concerns the gene INHA and colorectal adenocarcinoma.